证券代码：600276 证券简称：恒瑞医药 公告编号：临2025-160

Group 1 - The company approved a share repurchase plan using its own funds to implement an employee stock ownership plan, with a maximum repurchase price of RMB 90.85 per share and a total repurchase amount between RMB 1 billion and RMB 2 billion [1] - The repurchase period is set for 12 months from the date of board approval [1] Group 2 - In September 2025, the company repurchased 4.5724 million shares, representing 0.07% of the total share capital, with a maximum purchase price of RMB 70.00 per share and a minimum of RMB 67.20 per share, totaling RMB 315.4042 million paid (excluding transaction fees) [2] - As of September 30, 2025, the repurchase details remained the same, confirming the total shares repurchased and the amounts involved [2] Group 3 - The repurchase actions comply with relevant laws and regulations as well as the company's established repurchase plan [3] - The company will make repurchase decisions based on market conditions and will fulfill information disclosure obligations in a timely manner [4]